Lys-MDA

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.^[1][2][3][4] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.^[5]

Lys-MDA

Clinical data
ATC code	none
Identifiers
IUPAC name (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number	1391487-26-5
Chemical and physical data
Formula	C16H25N3O3
Molar mass	307.394 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN

See also

• Lisdexamfetamine
• Serdexmethylphenidate
• N-t-BOC-MDMA